MarketLens

Pricing Plans Sign Up Log in

Pro Investment Ideas

The $100 Billion Weight Loss Revolution That's Reshaping Your Portfolio

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market

1 months ago

SanDisk Just Joined the S&P 500—Here's What That Actually Means for Your Portfolio

5 months ago

From Value Meals to Weight-Loss Drugs: Navigating the Evolving Consumer Landscape

2 months ago

Is the AI Revolution Reshaping Mid-Cap Tech

2 months ago

GLP-1 Users Are Taking a Bite Out of the Restaurant Business

Restaurant operators are pivoting menus toward protein-heavy, smaller-portion offerings to retain customers using GLP-1 weight-loss medications. This strategic shift aims to mitigate declining demand ...

Stock News•1 day ago

GLP-1 Wars: Winners & Losers

Eli Lilly is establishing market dominance in the GLP-1 sector, leveraging its best-in-breed drug portfolio to capture significant share. This competitive positioning could solidify the company's long...

GLP

Stock News•1 day ago

Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight

Novo Nordisk reported that a higher-dose Wegovy regimen enabled patients to lose 28% of their body weight. The clinical data indicates that 84% of this weight reduction originated from body fat, while...

NVO

Stock News•6 days ago

Retatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLP

Unapproved weight-loss drug Retatrutide is seeing significant black-market demand ahead of its potential FDA approval. Eli Lilly’s next-generation treatment faces high consumer interest, signaling str...

GLP